The update introduces presentation queues, enhanced consult workflows, and speech-driven dictation capabilities for pathology labs.
PathAI has released AISight Dx v2.17, expanding its cloud-based digital pathology image management system with three new capabilities designed to support lab operations and translational research workflows.
The update introduces presentation queues integrated with AISight Live to help labs build, save, and share curated slide and case sets for tumor boards, education, and training. The system includes proactive case suggestions, automatic queueing from accession pages, bulk add functionality for cases or slides, drag and drop with reordering, and grouping by metadata with folder parity.
Users can create item nicknames and access shareable saved queues in a new Library > Queues tab, enabling dynamic, ready-for-presentation queues for tumor boards and teaching sessions.
Secondary Review Workflow Options
The release adds an optional, lab-configurable secondary review workflow that allows labs to maintain their current informal mentions and notifications approach or enable a structured flow. When enabled, the case assignment dashboard includes a secondary reviewer column for assigning pathologists, with assignees seeing a Mark Viewed control in the slide viewer.
Viewed or unviewed status appears on hover in the secondary reviewer column, and assignment and viewing alerts appear in the notification center. This provides a more formal, standardized process for consults while maintaining lab flexibility.
Voice-Enabled Reporting Integration
Through a collaboration with Voicebrook, AISight Dx now supports speech-driven dictation and structured reporting within the platform workflow. The integration connects slide review in AISight Dx with Voicebrook’s voice-enabled tools, which support dictation and voice commands for anatomic pathology workflows.
“AISight Dx v2.17 is built to make tumor boards and consults simpler and more effective, while giving pathologists finer-grained control over how they interact with algorithm results,” says Andy Beck, MD, PhD, chief executive officer and co-founder of PathAI, in a release. “With presentation queues, a flexible consult workflow, and annotation insights, teams can prepare, present, and collaborate with greater confidence and speed.”
AISight Dx is FDA-cleared for primary diagnosis in the US and is CE-IVD-marked for primary diagnosis in the EEA, UK, and Switzerland.
ID 141901747 © Andreusk | Dreamstime.com
